SK Bioscience is a South Korean biopharmaceutical company specializing in vaccine development and manufacturing. The company gained prominence during the COVID-19 pandemic as a key vaccine manufacturer and has since been positioning itself as a broader biologics player. Based on the consolidated financial statements (연결재무제표), the company operates through integrated pharmaceutical operations, though specific segment breakdowns are not detailed in the available filing data.
[TRANSLATION NOTE: Business description is based on general company knowledge; specific segment details were not included in the Korean financial filing data provided.]
SK Bioscience is experiencing significant revenue headwinds and profitability challenges. Revenue declined sharply to KRW 267.5 billion in FY2024 from KRW 369.5 billion in FY2023, representing a 27.6% year-over-year decrease. This continues a downward trend from the FY2022 peak of KRW 456.7 billion, reflecting waning pandemic-related vaccine demand.
The margin picture has deteriorated substantially. Operating profit swung from a loss of KRW 12.0 billion in FY2023 to a much larger loss of KRW 138.4 billion in FY2024. Net income turned negative at KRW -50.1 billion in FY2024 versus a profit of KRW 22.3 billion in FY2023.
Despite operational losses, the balance sheet shows expansion. Total assets increased 53.5% to KRW 2,844 billion at end-2024 from KRW 1,852 billion at end-2023, driven by non-current assets surging from KRW 469 billion to KRW 1,267 billion—likely reflecting significant capital investment in manufacturing capacity. However, total liabilities jumped dramatically from KRW 148.6 billion to KRW 821.1 billion, with non-current liabilities increasing from KRW 13.0 billion to KRW 510.6 billion. The debt-to-equity ratio remains relatively manageable at approximately 40.6%, but the sharp increase warrants monitoring. Retained earnings decreased from KRW 549.4 billion to KRW 499.8 billion, reflecting accumulated losses.
The filing data provided does not include ownership structure details or foreign ownership percentages. This information would typically be found in separate disclosure sections not included in the financial statement extracts provided.
[DATA LIMITATION: Ownership and foreign investor percentage data not available in provided filing.]
Revenue concentration risk: The sharp 41.4% revenue decline from FY2022 to FY2024 suggests heavy dependence on pandemic-era vaccine contracts that are not being replaced by sustainable revenue streams, creating business model uncertainty.
Capital intensity amid losses: The company invested heavily in non-current assets (up 170% year-over-year) while reporting widening operating losses of KRW 138 billion, creating a cash burn dynamic that may require additional financing if commercial products don't achieve market traction quickly.
SK Bioscience represents a high-risk bet on a vaccine manufacturer attempting to transition from pandemic-driven revenues to sustainable biologics operations while managing significant capital deployment and operational losses.
⚠️ This profile is AI-generated from DART filings. Quantitative data is reliable. Qualitative summaries should be verified against original Korean filings for investment decisions.